Tekmira Pharmaceuticals Corp (TKMR) (TKMR)

[Echo20]

Nano-Surf

NEW YORK (AP) -- Shares of Alnylam Pharmaceuticals Inc. rose Wednesday after a Piper Jaffray analyst upgraded the shares, saying the biotechnology company should achieve several milestones in 2013.

THE SPARK: Analyst Edward Tenthoff raised his rating to "Overweight" from "Neutral," saying Alnylam has several achievements to look forward to now that it has settled a licensing dispute with Tekmira Pharmaceuticals Corp.

Tenthoff said the company should report data from a mid-stage clinical trial of its drug ALN-TTR02 in the middle of 2013, and said Alnylam hopes to start clinical trials of injected versions of two drugs in 2013.
_______________________________________________________________

Anylam has some middle Clinical Trials going into 2012 and those each passed Clinical Trial Phase One and both passed with TKMR formulas that passed Clinical Phase One Trial!!!!!


TKMR formulas have passed a few Clinical Trials Phase One already.
Many companies get picked up after passing CLINICAL TRIAL PHASE ONE SAFETY IN HUMANS.

If TKMR passes on Clinical Trial Phase One for EBOLA that will be ANOTHER PHASE ONE PASS for TKMR, not the first! There is also TALON and MARQUIBO! (3?)

This also points to the reality the TKMR is in the MONEY LANE at this time.

Echo20